Jared Quay tells you why James Harden at +500 to win the MVP is a bargain.
Jared Quay tells you why James Harden at +500 to win the MVP is a bargain.
A UK study into using different COVID-19 vaccines in two-dose inoculations is being expanded to include shots made by Moderna and Novavax, researchers said on Wednesday. The trial, known as the Com-Cov study, was first launched in February to look at whether giving a first dose of one type of COVID-19 shot, and a second dose of another, elicits an immune response that is as good as using two doses of the same vaccine. The idea, said Matthew Snape, the Oxford University professor leading the trial, "is to explore whether the multiple COVID-19 vaccines that are available can be used more flexibly".
Kevin Durant scored 31 points on 11-for-15 shooting in his most productive performance in 2 1/2 months, as the Brooklyn Nets blew out the Minnesota Timberwolves 127-97 on Tuesday afternoon.
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Vroom, Inc. To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - April 13, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Vroom, Inc. ("Vroom" or the "Company") (NASDAQ:VRM) and reminds investors of the May 21, 2021 deadline to seek the role of lead plaintiff in a federal ...
For the past decade, Brandon Schneider watched every leader among the Golden State Warriors to see how they all operated. The Warriors promoted the 41-year-old Schneider to president and chief operating officer on Tuesday to replace Rick Welts, a Naismith Memorial Basketball Hall of Fame member who is moving to an advisory role after the season. Schneider will assume his new position July 1.
Embattled country star Morgan Wallen posted a four-page, handwritten note to his Instagram account Tuesday afternoon, telling fans that he has been working on himself during his time out of the limelight and will not be playing any concerts or festivals this summer. Wallen’s plans for country’s summer season have been a source of much […]
United States Capitol Police Officer William Evans, who died in the line of duty April 2, is lying in honor in the Capitol Rotunda.
Apr. 13—Sam Sandy homered and had four RBIs to lead Athens in an 18-14 win over Austin in high school baseball on Monday. Heath Carden doubled twice and drove in five runs for the Golden Eagles and Jon Martin Ricketts had two hits and three RBIs. Connor Beck had three hits and two RBIs and Jack Elliott drove in a pair of runs. Cameron Bracken led Austin with two hits and four RBIs. Jack ...
Combination therapy with belapectin suggests a better objective response rate with fewer adverse events than pembrolizumab (KEYTRUDA®) aloneNORCROSS, Ga., April 13, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that a paper published in the peer-reviewed Journal for ImmunoTherapy of Cancer (JITC), the highest ranked fully open access immunology journal, provides further clinical evidence that using belapectin, a potent galectin-3 inhibitor, in combination with pembrolizumab (KEYTRUDA®), a PD-1 inhibitor, significantly enhances tumor response to immunotherapy in patients with advanced metastatic melanoma (MM) and head and neck squamous cell carcinoma (HNSCC). The paper, titled “Enhancing Clinical and Immunological Effects of anti-PD-1 with Belapectin, a Galectin-3 Inhibitor” (doi:10.1136/jitc-2021-002371) describes results from an ongoing Phase 1 clinical study, a collaboration between Galectin Therapeutics and Providence Cancer Institute in Portland, Oregon. Following the recent publication of positive preclinical results that showed the inhibition of galectin-3 in combination with an agonist anti-OX40 monoclonal antibody reprograms the tumor microenvironment to favor anti-tumor activity, the current study tests the clinical hypothesis that galectin-3 blockade with belapectin in combination with pembrolizumab enhances tumor response for patients with advanced MM or HNSCC. In the study, as previously disclosed, an objective response was observed in 50% of MM (7/14) and 33% of HNSCC (2/6) patients. This compares favorably to published response rates on pembrolizumab alone. The authors noted that the combination was associated with fewer immune-mediated adverse events than anticipated with pembrolizumab alone. In addition, the analysis of patients’ tumor tissue revealed reduced monocytic myeloid-derived suppressor cells and increased effector memory T-cell activation in responders compared with non-responders. Also, an increased baseline expression of galectin-3 positive tumor cells correlated with clinical response. “Immunotherapy is a significant breakthrough in the treatment of many cancers, but tumor-induced immune suppression contributes to treatment resistance. Galectin-3 is an important driver of this tumor-induced immunosuppression, and this clinical study constitutes proof-of-concept that the addition of belapectin, a galectin-3 inhibitor, to a PD-1 inhibitor can benefit cancer patients,” said Dr. Brendan Curti, M.D., Earle A. Chiles Research Institute, a division of Providence, and the first author of the paper. “The analysis of patients’ tumor tissues is consistent with previously published pre-clinical data with belapectin and confirms the ability of belapectin to modulate the tumor microenvironment to favor anti-tumor activity. The possibility to improve the tolerance and safety of immunotherapy is also very exciting,” commented Pol F. Boudes, M.D., Chief Medical Officer of Galectin Therapeutics. “These proof-of-concept clinical data provide a strong rationale to initiate a randomized placebo-controlled phase 2 clinical trial to evaluate the efficacy and safety of belapectin in combination with a PD-1 inhibitor compared to a PD-1 inhibitor alone in this cancer patient population. We look forward to continuing our work with Providence Cancer Institute, and we anticipate the upcoming release of additional data from the expansion cohort in this study.” About Belapectin (GR-MD-02) Belapectin (GR-MD-02) is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of NASH and fibrosis. Galectin-3 plays a major role in diseases that involve scarring of organs including fibrotic disorders of the liver, lung, kidney, heart and vascular system. Belapectin binds to galectin-3 and disrupts its function. Preclinical data in animals have shown that belapectin has robust treatment effects in reversing liver fibrosis and cirrhosis. A Phase 2 study showed belapectin may prevent the development of esophageal varices in NASH cirrhosis; these results provide the basis for the conduct of the NAVIGATE trial. The NAVIGATE trial (NAVIGATEnash.com), entitled “A Seamless Adaptive Phase 2b/3, Double-Blind, Randomized, Placebo-controlled Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR-MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis” began enrolling patients in June 2020 and is posted on www.clinicaltrials.gov (NCT04365868). Galectin-3 also has a significant role in cancer, and the Company is supporting a Phase 1 study in combined immunotherapy of belapectin and KEYTRUDA in treatment of advanced melanoma and in head and neck cancer. About Galectin Therapeutics Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin (formerly known as GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH-related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are in treatment of combination immunotherapy for advanced melanoma and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com. About Providence Cancer Institute Providence Cancer Institute, a part of Providence St. Joseph Health, offers the latest in cancer services, including diagnostic, treatment, prevention, education, support and internationally renowned research. Providence Cancer Institute is home to the Earle A. Chiles Research Institute, a world-class research facility located within the Robert W. Franz Cancer Center in Portland, Oregon, and is a recognized leader in the field of cancer immunotherapy since 1993. Investigators lead more than 400 active clinical trials in key areas such as cancers of the: breast, colon/rectum, prostate, lung, esophagus, liver and pancreas, head and neck, ovary, skin and blood. Other studies are investigating treatments for COVID-19. Learn more at providenceoregon.org/cancer. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect” and others. They are based on management’s current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that Galectin’s development program for belapectin will lead to the first therapy for the treatment of fatty liver disease with cirrhosis and those regarding the hope that our lead compounds will be successful in cancer immunotherapy and in other therapeutic indications. Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements include, among others, that trial endpoints required by the FDA may not be achieved; Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of belapectin or any of its other drugs in development; the Company may not be successful in scaling up manufacturing and meeting requirements related to chemistry, manufacturing and control matters; the Company’s current NAVIGATE clinical trial and any future clinical studies as modified to meet the requirements of the FDA may not produce positive results in a timely fashion, if at all, and could require larger and longer trials, which would be time consuming and costly; plans regarding development, approval and marketing of any of Galectin’s drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies; regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials. Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations. Global factors such as COVID-19 may limit access to NASH patient populations around the globe and slow trial enrollment and prolong the duration of the trial and significantly impact associated costs as well as impact other trial related activities including, amongst others, manufacturing and regulatory reviews. For a discussion of additional factors impacting Galectin’s business, see the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements. Company Contact:Jack Callicutt, Chief Financial Officer(678) email@example.com Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics’ galectin-3 inhibitor GR-MD-02.
Shinhan Bank (KRX: 055550), the leading bank in South Korea, has joined the Hedera Governing Council, the body that oversees distributed governance of the Hedera network.
TIGA, the games industry trade association, is pleased to announce the re-accreditation of the following games courses at Sheffield Hallam University:
Singer posts handwritten note thanking fans for the support of his album 'Dangerous'
On Tuesday morning, the U.S. Food and Drug Administration and the Centers for Disease Control and Prevention recommended “out of an abundance of caution” that states pause the use of Johnson & Johnson’s single-dose COVID-19 vaccine.
Bieber is performing standout tracks from his newly released studio album, 'Justice.' After the event, he'll host an afterparty for his YouTube Premium fans.
A group of senators introduced the 'CRUISE Act' which would override the CDC's restrictions on the cruise industry and allow ships to sail.
Univision is buying Grupo Televisa’s content assets in a $4.8 billion transaction that will combine two of the biggest Spanish-language producers in the world into one powerhouse companies. Televisa, which is based in Mexico, will see its content and media assets will be rolled into Univision and create a new company called Televisa-Univision. The combination brings together the two leading media businesses in the two largest Spanish-speaking markets in the world: Univision in the United States, the largest Spanish-language media market by value, and Televisa in Mexico, which is the most populous Spanish-language market in the world. Univision is paying Televisa $3 billion in cash, with another $1.45 billion in equity. The total value of the transaction is $4.8 billion. Televisa-Univision will get a $1 billion equity investment by a consortium led by SoftBank Group. Televisa will be the largest shareholder in Televisa-Univision with an equity stake of approximately 45%. As a part of the agreement, Televisa will retain ownership of izzi Telecom, Sky, and other businesses, as well as the main real estate associated with the production facilities, the broadcasting licenses and transmission infrastructure in Mexico. Televisa will also contribute its four free-to-air channels, 27 pay-TV networks channels and stations, its Videocine movie studio and Blim TV subscription video on demand (SVOD) service; and the Televisa trademark. These media assets comprise the definitive market leader in Mexico. “This transformative combination brings together the leading network serving U.S. Spanish-language audiences with the leading media platform in Mexico powered by the most powerful Spanish-language content engine in the world,” said Univision CEO Wade Davis. “Televisa-Univision will emerge as the leading global Spanish-language multi-media company, uniquely positioned to capture the significant market opportunity for Spanish speakers worldwide.” Read original story Univision Buys Televisa’s Content Assets in $4.8 Billion Deal At TheWrap
The event will be livestreamed on April 28th, and the invite teases that "the most powerful Galaxy is coming."
WILMINGTON, Del., April 13, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating: Support.com, Inc. (NASDAQ GS: SPRT) regarding possible breaches of fiduciary duties and other violations of law related to Support.com’s agreement to merge with Greenridge Generation Holdings Inc. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-supportcom-inc. RumbleOn, Inc. (NASDAQ GS: RMBL) regarding possible breaches of fiduciary duties and other violations of law related to RumbleOn’s agreement to merge with RideNow. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-rumbleon-inc. SYNNEX Corporation (NYSE: SNX) regarding possible breaches of fiduciary duties and other violations of law related to SYNNEX’s agreement to merge with Tech Data Corporation. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-synnex-corporation. Frank’s International N.V. (NYSE: FI) regarding possible breaches of fiduciary duties and other violations of law related to Frank’s International’s agreement to merge with Expro Group Holdings International Limited. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-franks-international-nv. You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or firstname.lastname@example.org. Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide. Attorney advertising. Prior results do not guarantee a similar outcome. CONTACT: Rigrodsky Law, P.A.Seth D. RigrodskyGina M. Serra(888) 969-4242 (Toll Free)(302) 295-5310Fax: (302) email@example.com https://rl-legal.com
The Barry Callebaut Group, the world's leading manufacturer of high-quality chocolate and cocoa products, announced that Denis Convert will be appointed Managing Director for Australia and New Zealand, effective August 1, 2021.
VANCOUVER, British Columbia, April 13, 2021 (GLOBE NEWSWIRE) -- Madison Pacific Properties Inc. (the Company) (TSX: MPC and MPC.C), a Vancouver-based real estate company announces the results of operations for the six months ended February 28, 2021. The results reported are pursuant to International Financial Reporting Standards (IFRS) for public companies. For the six months ended February 28, 2021, the Company is reporting net income of $22.3 million (2020: $14.7 million); cash flows from operating activities before changes in non-cash operating balances of $4.9 million (2020: $7.0 million); and income per share of $0.34 (2020: $0.25). Included in net income is an after-tax net gain from the fair value adjustment on investment properties of $14.9 million (2020: $9.9 million). The Company currently owns approximately $628 million in investment and development properties, including the Company’s proportionate share of properties held through jointly-controlled partnerships. The Company’s investment portfolio comprises 52 properties with approximately 1.83 million rentable sq. ft. of industrial and commercial space and a 50% interest in a 54 unit multi-family rental property. Approximately 98.9% of available space within the industrial and commercial investment properties is currently leased. The Company’s development properties include a 50% interest in the Silverdale Hills Limited Partnership which owns approximately 1,389 acres of undeveloped residential designated lands in Mission, British Columbia. Approximately 38 acres of these residential lands in Mission are currently under development as townhomes and single family lots for sale. Construction of the first phase of the development of 34 townhomes commenced in late 2020. Sales for the townhomes and single family lots are expected to commence in the third quarter of fiscal 2021. The COVID-19 pandemic has continued to cause economic disruption and it is difficult to predict the duration and extent of the pandemic and whether it will have any long-term impact on the Company’s business. The Company is currently well positioned, with a diversified income portfolio of industrial, office, retail and multi-family rental assets. Approximately 82% of the Company’s commercial investment properties are located in British Columbia where the provincial government has various social gathering and business restrictions in place. The Company has provided some short-term rent deferrals and rent relief, including rent relief through government assistance programs, for certain tenants that have been significantly affected by the COVID-19 pandemic. As at February 28, 2021, outstanding repayable rent deferrals amounted to $324 thousand and rent relief for the six months ended February 28, 2021, amounted to $105 thousand. These are uncertain and challenging times and management will be continuing to monitor business developments and market conditions and any effect they may have on the business. For a review of the risks and uncertainties to which the Company is subject see its most recently filed annual and interim MD&A. The Company announced today that it has declared the payment of a special cash dividend of $0.34 per Class B voting common share and Class C non-voting share payable on May 4, 2021 to shareholders of record on April 23, 2021. The amount of the special one-time dividend allows the Company to continue to pursue real estate opportunities while returning some capital to shareholders. The special dividend is in addition to any dividends that may be declared pursuant to the regular dividend policy of the Company. The dividend is an eligible dividend for Canadian tax purposes. The Board of Directors is also pleased to announce that Mr. John DeLucchi has been appointed to the Board of Directors of the Company. Mr. DeLucchi was recently appointed President and Chief Executive Officer of Madison Venture Corp. Before joining Madison Venture Corp., Mr. DeLucchi was a partner at PricewaterhouseCoopers LLP and was in the role of British Columbia Managing Partner from 2009 to 2017. The Board of Directors are pleased to have Mr. DeLucchi join them and look forward to working with him. Contact:Mr. Marvin HaasenMs. Bernice Yip President & CEOInvestor InformationTelephone:(604) 732-6540 (604) 732-6540Fax:(604) 732-6550 Address:389 West 6th Avenue Vancouver, B.C. V5Y 1L1
DALLAS, April 13, 2021 (GLOBE NEWSWIRE) -- NexPoint Strategic Opportunities Fund (NYSE:NHF) (“NHF”) today announced the extension of the offering period for its previously announced offer to purchase any and all Shares of Beneficial Interest (the “Shares”) of United Development Funding IV (“UDFI” or the “Company”) at a price of $1.10 per Share upon the terms and subject to the conditions set forth in the Offer to Purchase and in the related Assignment Form for the offer (which together constitute the “Offer” and the “Tender Offer Documents”). The Offer is now scheduled to expire at 12:00 midnight, Eastern Time, at the end of the day on May 14, 2021, unless the Offer is extended or earlier terminated. The Tender Offer Documents are available at www.UDFITenderOffer.com, or from the information agent for the Offer, as discussed below. As previously announced on December 14, 2020, the Offer is conditioned upon, among other things, the satisfaction or waiver of the following conditions: (i) there shall not have been threatened, instituted, or pending any action or proceeding before any court or any governmental or administrative agency (a) challenging the acquisition of shares pursuant to the Offer or otherwise relating in any manner to the Offer, or (b) in the sole judgment of NHF, otherwise materially adversely affecting the Company; (ii) NHF shall have received all required governmental approvals, if any, for the Offer; (iii) NHF shall have had the opportunity to conduct sufficient due diligence to determine whether the offered price per share is reasonable given the current financial condition and results of operations of UDFI; (iv) the Board of Trustees of UDFI shall have waived in writing the ownership limitations set forth in Article VII of the Declaration of Trust of UDFI as such limitations would otherwise apply to the Offer; and (v) NHF shall have received satisfactory evidence that UDFI has continued to qualify as a real estate investment trust (“REIT”) under federal tax laws and thereby to avoid any entity-level federal income or excise tax. On January 8, 2021, UDFI announced that it had reduced the percentage of outstanding Shares that a shareholder may own from 9.8% to 5.0%. The Company took such action in an effort to frustrate the Offer. It also announced it amended the Company’s bylaws to require that certain legal actions could be brought on behalf of or against UDFI only in certain courts in Maryland. NHF and its advisors are reviewing these actions and their legality under applicable law. Shareholders should read the Offer to Purchase and the related materials carefully because they contain important information. Shareholders may obtain a free copy of the Offer to Purchase and the Assignment Form from D.F. King & Co., Inc., the information agent for the Offer (the “Information Agent”), by calling toll-free at (800) 331-7543. THE OFFER WILL EXPIRE AT 12:00 MIDNIGHT, EASTERN TIME, AT THE END OF THE DAY ON MAY 14, 2021, UNLESS THE OFFER IS EXTENDED OR EARLIER TERMINATED. About the NexPoint Strategic Opportunities Fund (NHF) The NexPoint Strategic Opportunities Fund (NYSE:NHF) is a closed-end fund managed by NexPoint Advisors, L.P. that is in the process of converting to a diversified REIT. On August 28, 2020, shareholders approved the conversion proposal and amended the Company’s fundamental investment policies and restrictions to permit the Company to pursue its new business. The Company has since realigned its portfolio so that it is no longer an “investment company” under the Investment Company Act of 1940 (the “1940 Act”). On March 31, 2021, the Company filed an application with the Securities and Exchange Commission (the “SEC”) for an order under the 1940 Act declaring that the Company no longer operate as an investment company (the “Deregistration Order”). During the SEC’s review process, the Company will continue to be structured as a closed-end investment fund. The Company has also completed the repositioning of its investment portfolio sufficient to achieve REIT tax status and is operating during its 2021 taxable year so that it may qualify for taxation as a REIT. For more information visit www.nexpoint.com/nexpoint-strategic-opportunities-fund About NexPoint Advisors, L.P. NexPoint Advisors, L.P. (the “Investment Adviser”) is an SEC-registered adviser on the NexPoint alternative investment platform. It serves as the adviser to a suite of funds and investment vehicles, including a closed-end fund, interval fund, business development company, and various real estate vehicles. For more information visit www.nexpoint.com — Risks and Disclosures This document is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any common stock of UDFI or any other securities. The offer to purchase common stock of UDFI will only be made pursuant to the Offer to Purchase, the Assignment Form and related documents. THE TENDER OFFER MATERIALS (INCLUDING THE OFFER TO PURCHASE, THE ASSIGNMENT FORM AND CERTAIN OTHER TENDER OFFER DOCUMENTS) WILL CONTAIN IMPORTANT INFORMATION. STOCKHOLDERS OF UDFI ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT SUCH STOCKHOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES. Investors and security holders may obtain a free copy of these statements (when available) by directing such requests to the Information Agent, by calling toll-free at (800) 331-7543. ### Media Contact Lucy Bannon firstname.lastname@example.org